Pharmacokinetics and Pharmacodynamics of Fructose
|Study Design:||Time Perspective: Prospective|
|Official Title:||Pharmacokinetics and Pharmacodynamics of Fructose Following Soft Drink Consumption: Sucrose vs High Fructose Corn Syrup|
- Fructose [ Time Frame: baseline, 15min, 30 min, 60 min, 90 min, 2 hr, 3 hr, 4.5 hr, 6 hr ]
- serum uric acid [ Time Frame: baseline, 15 min, 30 min, 60 min, 90 min, 2 hr, 3 hr, 4.5 hr, 6 hr ]
- glucose [ Time Frame: baseline, 15 min, 30 min, 60 min, 90 min, 2 hr, 3 hr, 4.5 hr, 6 hr ]
- lactate [ Time Frame: baseline, 15 min, 30 min, 60 min, 90 min, 2 hr, 3 hr, 4.5 hr, 6 hr ]
- triglycerides [ Time Frame: baseline, 15 min, 30 min, 60 min, 90 min, 2 hr, 3 hr, 4.5 hr, 6 hr ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2008|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
General public. Those who are not currently taking any medication besides birth control pills.
Other: Dr Pepper sweetened with sucrose or high fructose corn syrup
Comparison of different formulations of fructose.
Fructose consumption has risen sharply during the past several decades. Since its introduction to the United States in 1967, high fructose corn syrup (HFCS) has overtaken sucrose as the main sweetener in manufactured foods and beverages, and thus, is responsible for the approximately 30% increase in fructose in our diet. Numerous studies have shown that excessive fructose consumption can cause a variety of harmful metabolic effects, suggesting that fructose may partially be responsible for the current epidemic in obesity, hypertension, metabolic syndrome, and diabetes.
This preliminary study will investigate the pharmacokinetics and pharmacodynamics of fructose in a broad population. Specifically, the goal of our research are to compare the impact of the two main sources of dietary fructose, sucrose versus HFCS, on fructose bioavailability and acute metabolic changes by measuring response phenotypes, such as serum uric acid, lactate, and triglyceride levels.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00661947
|United States, Florida|
|University of Florida, Department of Pharmacy Practice, Center for Pharmacogenomics|
|Gainesville, Florida, United States, 32610|
|Principal Investigator:||Julie A Johnson, Pharm.D.||University of Florida|